Brown Advisory
AURA icon

Brown Advisory’s Aura Biosciences AURA Stock Holding History

Brown Advisory’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89.6K Hold
13,400
– – ﹤0.01% 1370
2025
Q4 		$73K Buy
+13,400
New +$79.6K ﹤0.01% 1369

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Brown Advisory's AURA Position: Q1 2026 in Review

Brown Advisory held its Aura Biosciences (AURA) position steady in Q1 2026 at 13,400 shares worth $89.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

Brown Advisory first reported a position in AURA in Q4 2025 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

  • Brown Advisory held 13,400 shares of Aura Biosciences worth $89.6K as of Q1 2026.
  • Brown Advisory left its Aura Biosciences share count unchanged in Q1 2026.
  • Aura Biosciences made up ﹤0.01% of Brown Advisory's portfolio in Q1 2026, its #1370 holding.
  • Brown Advisory first reported a position in Aura Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.